focus -WSS

focus

author：explore 2025-08-25 08:46:45 - browse：524

3D dollar signs come out of a prescription drug bottle — coverage from STAT — Adobe

WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s new power to negotiate drug prices, according to Congress’ nonpartisan budget experts.

The Inflation Reduction Act includes two measures that directly lower drug prices. Medicare price negotiation is the most controversial of the two. The law gives drugs 9 years on the market before negotiated prices take effect; biologics get 13 years. Drugs are selected for negotiation among the 50 top-selling drugs without generic or biosimilar competition. Medicare will negotiate prices for 10 drugs to start. Up to 60 drugs will be subject to negotiation over the next four years, and up to 20 more drugs every year afterward.

The law also requires drug companies to pay back Medicare when they raise prices on drugs faster than inflation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Adopting new red light myopia treatments may be short

WSS

Surgery pushed Ben Carson to fame

Readout LOUD podcast: possible new ALS drug, artificial wombs

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

AstraZeneca stays mum on Medicare drug pricing negotiations

Top private equity targets in 2023: cardiology, clinical trials, lasers

Biotech stock slump in 2023: awaiting the turnaround

leisure time

focus

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Cano Health’s bankruptcy is a warning for Medicare Advantage

Hollywood unions extend contract negotiations for actors

Drug for rare kidney disease narrowly misses mark in clinical trial

Tori Bowie and the unacceptable rates of Black maternal death

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Medicare proposal to cover medical devices draws a mixed reaction

Intarcia’s device

Novavax promises a turnaround & Lilly roils the obesity market

CDC's new outbreak response network to include Northeastern

explore

EpiPen alternative approval delay highlights citizen petition issue

Senators: Long

Devoted Health’s losses in Medicare Advantage persist

AstraZeneca stays mum on Medicare drug pricing negotiations

AstraZeneca stays mum on Medicare drug pricing negotiations

Why are Kaiser Permanente staff considering a strike?

entertainment

hotspot

hotspot

explore